Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.UK-based gene and cell therapy group Oxford Biomedica has partnered with non-profit Vaccines Manufacturing and Innovation Centre (VMIC) for the manufacturing of viral vector-based vaccines.
Oxford Biomedica and VMIC are members of the Oxford University manufacturing consortium formed to scale-up the production of Covid-19 vaccine candidate, AZD1222.
AstraZeneca is responsible for the manufacturing, development and distribution of the vaccine candidate globally. Last month, the pharmaceutical giant signed an initial clinical and commercial supply agreement with Oxford Biomedica for several batches.